Bionoid Pharma, Inc. Announces Completion of 2022 and 2023 Financial Audits by PCAOB-Registered Firm
-
Ayuso happy to fly under radar at Tour de France
-
Iran leaders pay last respects to Khamenei as mourners gather
-
Curran ready to fill England gap left by Stokes exit
-
UN issues 'red alert' over 'catastrophe' in Sudan's El-Obeid
-
Djokovic has history on the line at Wimbledon
-
Tour de France to start with team time-trial 'bang'
-
Hamilton sparkles in Silverstone sunshine
-
Dressed for success: Osaka reaches Wimbledon last 16 for first time
-
Swift and Kelce set to tie the knot in glitzy arena extravaganza
-
Bayern sign Germany defender Brown until 2031
-
Police hunt for Ukrainian woman over Monaco bomb attack
-
MEXC's June Highlights: $437 Billion in Trading Volume, Offering Access to 7,000+ US Stocks and ETFs
-
Kenya's abortion taboo is killing thousands of women
-
Stocks mostly rise as beaten-down tech stocks enjoy bounce
-
Madonna returns to form with dancefloor filler "Confessions II"
-
Iranian leaders pay respects to supreme leader as Tehran prepares for funeral
-
Dean says Australia final a 'fresh start' for England
-
Doubles not a 'carnival sideshow' say players amid schedule row
-
Wimbledon giving Serena 'as much time' as possible for doubles
-
Klopp in 'talks' for Germany job after Nagelsmann exit: federation
-
Chinese investors flock to Hong Kong as trading curbs tighten
-
Surging real estate development divides opinion on Athens' riviera
-
Projected 'super typhoon' heads for US Pacific islands
-
Move over, Messi! Robot footballers thrill crowds in South Korea
-
UN warns of strong looming El Nino
-
France deaths rose by 30% during heatwave
-
Hunt for last signs of life in Venezuela quake zone
-
Drones spot sharks 73 times in two days off Sydney beaches
-
Asian markets rise as beaten-down tech stocks enjoy bounce
-
Supreme leader's body arrives at Tehran religious complex for funeral
-
David v Goliath as Cape Verde face Messi's Argentina at World Cup
-
Mbappe's French juggernaut face Paraguay, eye World Cup quarter-finals
-
Nagelsmann quits as Germany coach after World Cup exit: reports
-
Wallabies riding wave of patriotic support against Ireland
-
All Blacks return to Christchurch 'a blessing', says Savea
-
Belgium opens up Congo archives amid global minerals race
-
'Not a museum': Slovak UNESCO village strains under tourism
-
Wimbledon clings onto fashion traditions, with a twist
-
DR Congo opposition builds against presidential third-term bid
-
Death toll from massive strikes on Kyiv rises to 30
-
China sports brands score NBA stars to assist global ambitions
-
El Nino set to be strong, UN warns
-
Man dies after setting self ablaze outside UN in New York: police
-
'Inspired millions': Modric praised as World Cup career appears at end
-
VAR 'taking joy' from football says Croatia coach Dalic after loss
-
Death toll hits 10 in Thai monk procession crash
-
Afghans come home but risk exclusion without any ID
-
Asian markets rise as beaten tech stocks enjoy respite from selling
-
'Coincidence of life' says Ronaldo after Jota tribute a year from death
-
'Royal wedding': Swift and Kelce kick off star-studded celebrations
Bionoid Pharma, Inc. Announces Completion of 2022 and 2023 Financial Audits by PCAOB-Registered Firm
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the successful completion of its financial audits for the fiscal years 2022 and 2023 by Olayinka Oyebola & Co., a PCAOB-registered firm. This milestone marks a significant step in Bionoid's commitment to financial transparency and regulatory compliance as the company continues executing its long-term growth strategy.
Olayinka Oyebola & Co. has worked diligently to complete the audits in accordance with Public Company Accounting Oversight Board (PCAOB) standards, ensuring the accuracy and integrity of Bionoid's financial reporting. The firm remains on track to finalize the company's 2024 financial statements as scheduled, further strengthening Bionoid's financial standing.
"The completion of our 2022 and 2023 audits is a critical achievement for Bionoid and underscores our dedication to financial accountability," said Wayne Cockburn, CEO of Bionoid Pharma, Inc. "As we continue our expansion through strategic acquisitions and AI-driven growth initiatives, maintaining strong financial governance remains a top priority. We appreciate the expertise and professionalism of Olayinka Oyebola & Co. and look forward to the timely completion of our 2024 financials."
Bionoid remains focused on scaling its operations through revenue-generating e-commerce acquisitions and the integration of its AI Maverick platform, positioning the company for sustainable growth and enhanced investor confidence.
About Bionoid Pharma, Inc.
Bionoid Pharma, Inc. is a forward-thinking health and wellness company dedicated to expanding revenue streams and brand presence through strategic acquisitions and advanced AI technology. Its proprietary AI Maverick platform enhances customer engagement and operational efficiency, supporting the company's mission to deliver innovative, AI-driven solutions for long-term growth.
Stay connected:
Website: BionoidPhama.com
OTC Markets: BINP
For further information, contact:
Wayne Cockburn, CEO
Phone: (905) 505-0770
Email: [email protected]
SOURCE: Bionoid Pharma, Inc.
View the original press release on ACCESS Newswire
O.M.Souza--AMWN
